DE60040383D1 - Gentherapie für diabetische ischämie - Google Patents
Gentherapie für diabetische ischämieInfo
- Publication number
- DE60040383D1 DE60040383D1 DE60040383T DE60040383T DE60040383D1 DE 60040383 D1 DE60040383 D1 DE 60040383D1 DE 60040383 T DE60040383 T DE 60040383T DE 60040383 T DE60040383 T DE 60040383T DE 60040383 D1 DE60040383 D1 DE 60040383D1
- Authority
- DE
- Germany
- Prior art keywords
- gene therapy
- diabetic
- diabetic ischemia
- ischemia
- ischemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30998499 | 1999-10-29 | ||
PCT/JP2000/007502 WO2001032220A1 (fr) | 1999-10-29 | 2000-10-26 | Therapie genique pour traiter les maladies ischemiques diabetiques |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60040383D1 true DE60040383D1 (de) | 2008-11-13 |
Family
ID=17999746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60040383T Expired - Lifetime DE60040383D1 (de) | 1999-10-29 | 2000-10-26 | Gentherapie für diabetische ischämie |
Country Status (15)
Country | Link |
---|---|
US (3) | US20080268030A1 (de) |
EP (1) | EP1142590B8 (de) |
JP (1) | JP3877148B2 (de) |
KR (1) | KR20010108053A (de) |
CN (1) | CN1182874C (de) |
AT (1) | ATE409494T1 (de) |
AU (1) | AU778826B2 (de) |
CA (1) | CA2356701C (de) |
CY (1) | CY1110445T1 (de) |
DE (1) | DE60040383D1 (de) |
DK (1) | DK1142590T3 (de) |
ES (1) | ES2313907T3 (de) |
HK (1) | HK1041211A1 (de) |
PT (1) | PT1142590E (de) |
WO (1) | WO2001032220A1 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60038869D1 (de) | 1999-10-08 | 2008-06-26 | Anges Mg Inc | Hgf zur gentherapie der karidomyopathie |
WO2002089854A1 (fr) | 2001-05-09 | 2002-11-14 | Anges Mg, Inc. | Transfert de genes et facteur angiogenique pour maladie de la peau |
JP4441263B2 (ja) | 2001-11-28 | 2010-03-31 | アンジェスMg株式会社 | 神経変性疾患遺伝子治療剤 |
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
US20080213348A1 (en) * | 2002-06-06 | 2008-09-04 | Anges Mg, Inc. | Agents for gene therapy of cerebrovascular disorders |
JP4533144B2 (ja) | 2002-10-02 | 2010-09-01 | アンジェスMg株式会社 | 聴覚機能障害用医薬 |
JP4775940B2 (ja) * | 2004-06-29 | 2011-09-21 | アンジェスMg株式会社 | アロディニアの治療、改善、予防剤 |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
JP5579164B2 (ja) * | 2008-04-09 | 2014-08-27 | ビロメッド カンパニー, リミテッド | 凍結乾燥dna製剤、組成物、及び凍結乾燥dna製剤を製造する方法 |
JP5977440B2 (ja) * | 2012-04-27 | 2016-08-24 | アイマゴ ソシエテ アノニムAimago S.A. | 光コヒーレントイメージング医療デバイス |
EP3061457B1 (de) | 2013-10-22 | 2020-01-22 | Helixmith Co., Ltd | Zusammensetzung zur prävention oder behandlung von amyotropher lateralsklerose mit zwei oder mehr isoformen des hepatozytenwachstumsfaktors |
RU2691654C1 (ru) * | 2018-06-05 | 2019-06-17 | Юрий Валентинович Червяков | Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии бедренной и подколенной артерий |
CA3106297A1 (en) | 2018-07-19 | 2020-01-23 | Helixmith Co., Ltd. | Lyophilized pharmaceutical compositions for naked dna gene therapy |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4576177A (en) * | 1983-02-18 | 1986-03-18 | Webster Wilton W Jr | Catheter for removing arteriosclerotic plaque |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5631237A (en) * | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
TW404844B (en) * | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US5817022A (en) * | 1995-03-28 | 1998-10-06 | Sonometrics Corporation | System for displaying a 2-D ultrasound image within a 3-D viewing environment |
US5756122A (en) * | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
CA2230819C (en) * | 1995-08-29 | 2009-04-14 | Sumitomo Pharmaceuticals Co., Ltd. | Medicament comprising hgf gene |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
US6893664B1 (en) * | 1996-06-17 | 2005-05-17 | Powderject Research Limited | Particle delivery techniques |
WO1998000543A1 (en) * | 1996-07-03 | 1998-01-08 | Genentech, Inc. | Hepatocyte growth factor receptor agonists and uses thereof |
US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
US6024703A (en) * | 1997-05-07 | 2000-02-15 | Eclipse Surgical Technologies, Inc. | Ultrasound device for axial ranging |
GB9709453D0 (en) * | 1997-05-10 | 1997-07-02 | Imp Cancer Res Tech | Polypedtides and their use in therapy |
WO1999036103A1 (en) * | 1998-01-16 | 1999-07-22 | Mcgill University | Prevention and treatment of neuropathy by hepatocyte growth factor |
CA2261255A1 (en) * | 1998-02-13 | 1999-08-13 | Ethicon, Inc. | Assessment of ischemic wound healing therapeutics |
US6066123A (en) * | 1998-04-09 | 2000-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of bioavailability by use of focused energy delivery to a target tissue |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
US7125856B1 (en) * | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
EP1169052B1 (de) * | 1999-04-15 | 2005-07-20 | Caritas St. Elizabeth's Medical Center of Boston, Inc. | Vegf angiogenische wachstumsfaktoren zur behandlung von peripheren neuropathie |
US6440945B1 (en) * | 1999-05-27 | 2002-08-27 | Instituto Dermopatico Dell'immacolata | Method of inducing angiogenesis in nonis chemic skeletal muscle |
DE60038869D1 (de) * | 1999-10-08 | 2008-06-26 | Anges Mg Inc | Hgf zur gentherapie der karidomyopathie |
ATE395071T1 (de) * | 2000-06-27 | 2008-05-15 | Anges Mg Inc | Pharmazeutische zubereitungen zur angiogenese- therapie |
WO2002089854A1 (fr) * | 2001-05-09 | 2002-11-14 | Anges Mg, Inc. | Transfert de genes et facteur angiogenique pour maladie de la peau |
US20060074036A1 (en) * | 2002-06-06 | 2006-04-06 | Ryuichi Morishita | Agents for gene therapy of cerebrovascular disorders |
US20080213348A1 (en) * | 2002-06-06 | 2008-09-04 | Anges Mg, Inc. | Agents for gene therapy of cerebrovascular disorders |
CN1717254A (zh) * | 2002-12-02 | 2006-01-04 | 安增子摩祺株式会社 | 用于治疗或预防血管生成-依赖性症状的组合物 |
-
2000
- 2000-10-26 CN CNB00803835XA patent/CN1182874C/zh not_active Expired - Lifetime
- 2000-10-26 WO PCT/JP2000/007502 patent/WO2001032220A1/ja active IP Right Grant
- 2000-10-26 DE DE60040383T patent/DE60040383D1/de not_active Expired - Lifetime
- 2000-10-26 PT PT00971697T patent/PT1142590E/pt unknown
- 2000-10-26 JP JP2001534424A patent/JP3877148B2/ja not_active Expired - Lifetime
- 2000-10-26 AT AT00971697T patent/ATE409494T1/de active
- 2000-10-26 KR KR1020017008242A patent/KR20010108053A/ko not_active Application Discontinuation
- 2000-10-26 EP EP00971697A patent/EP1142590B8/de not_active Expired - Lifetime
- 2000-10-26 CA CA2356701A patent/CA2356701C/en not_active Expired - Lifetime
- 2000-10-26 ES ES00971697T patent/ES2313907T3/es not_active Expired - Lifetime
- 2000-10-26 AU AU10523/01A patent/AU778826B2/en not_active Expired
- 2000-10-26 DK DK00971697T patent/DK1142590T3/da active
-
2002
- 2002-04-09 HK HK02102637.3A patent/HK1041211A1/zh unknown
-
2008
- 2008-04-04 US US12/080,715 patent/US20080268030A1/en not_active Abandoned
- 2008-12-22 CY CY20081101477T patent/CY1110445T1/el unknown
-
2010
- 2010-11-02 US US12/938,128 patent/US20110045061A1/en not_active Abandoned
-
2015
- 2015-09-28 US US14/867,866 patent/US20160250290A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2313907T3 (es) | 2009-03-16 |
KR20010108053A (ko) | 2001-12-07 |
US20080268030A1 (en) | 2008-10-30 |
EP1142590A1 (de) | 2001-10-10 |
EP1142590B8 (de) | 2008-11-26 |
CN1182874C (zh) | 2005-01-05 |
JP3877148B2 (ja) | 2007-02-07 |
EP1142590B1 (de) | 2008-10-01 |
CN1339973A (zh) | 2002-03-13 |
PT1142590E (pt) | 2008-10-27 |
ATE409494T1 (de) | 2008-10-15 |
AU1052301A (en) | 2001-05-14 |
AU778826B2 (en) | 2004-12-23 |
US20160250290A1 (en) | 2016-09-01 |
EP1142590A4 (de) | 2005-01-26 |
DK1142590T3 (da) | 2009-01-26 |
CA2356701A1 (en) | 2001-05-10 |
WO2001032220A1 (fr) | 2001-05-10 |
CA2356701C (en) | 2011-02-15 |
HK1041211A1 (zh) | 2002-07-05 |
US20110045061A1 (en) | 2011-02-24 |
CY1110445T1 (el) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110445T1 (el) | Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια | |
ATE283701T1 (de) | Metabolische intervention mit glp-1 zur verbesserung der funktion von ischämischem und wiederdurchblutetem gewebe | |
BR0012450A (pt) | Benzimidazóis substituìdos | |
BR0111438A (pt) | Análogos de ácido barbitúrico como agentes terapeuticos | |
TR200101307T2 (tr) | Antranilik asit amidler ve ilaç olarak kullanılmaları. | |
EA200101155A1 (ru) | Противоопухолевые соединения, активируемые протеином активации фибробластов (fap) | |
DK92688D0 (da) | Polypeptid, dna og anvendelse deraf | |
DK2070939T3 (da) | Modulatorer af farmakologiske midler | |
ATE442851T1 (de) | 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a | |
ES2092460T1 (es) | Composicion donadora de oxido nitrico y procedimiento para el tratamiento de trastornos anales. | |
EE05302B1 (et) | 4-fluoro-N-(indaan-2-l)bensamiidi kasutamine ja protsess ravimi valmistamiseks | |
DE69832702D1 (de) | Menschliche chinon reduktase konjugate für adept und gdept | |
ATE428719T1 (de) | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors | |
UY26677A1 (es) | Heterociclos que son inhibidores de la enzima impdh | |
DK0378086T3 (da) | Anvendelse af det aktive stof azelastin til bekæmpelse af psoriasis-sygdomme | |
HUP9900681A2 (hu) | TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban | |
DE3879873D1 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE516366T1 (de) | Regulierte aptamer-therapeutika | |
ATE270306T1 (de) | Einkettige insulinanaloge | |
CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
ATE151977T1 (de) | Therapeutisch wirksame, örtliche anwendung von st1435 | |
DK2359853T3 (da) | Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese | |
DE69016866D1 (de) | Verwendung von Bis(4-hydroxyphenylthio)methan-Derivaten zur Behandlung von Diabetes mellitus. | |
HUP0103557A2 (hu) | Antraciklinszármazék alkalmazása májtumor kezelésére | |
HUP9800247A2 (hu) | Humán endoglin gén promóter és annak alkalmazása |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |